Literature DB >> 19332097

Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.

Reiji Yoshimura1, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Nobuhisa Ueda, Jun Nakamura.   

Abstract

In the present study, we compared plasma levels of interleukin-6 (IL-6), tumor necrosis factor-alpha(TNFalpha), and brain-derived neurotrophic factor (BDNF) among selective serotonin reuptake inhibitor (SSRI)- or serotonin noradrenaline reuptake inhibitor (SNRI)-responsive depressed patients (n=31), SSRI- or SNRI-refractory depressed patients (n=20), and healthy controls (n=30). The plasma levels of IL-6 and TNF-alpha were significantly higher in depressed patients than in healthy controls. Treatment with antidepressants significantly reduced plasma levels of IL-6 and TNF-alpha. In addition, the plasma IL-6 level, but not the plasma TNF-alpha level, was higher in SSRI-refractory than SSRI-responsive depressed patients, and higher in SNRI-refractory than SNRI-responsive depressed patients. On the other hand, the plasma BDNF level was significantly lower in depressed patients than in healthy controls, whereas no difference was found in plasma BDNF levels between SSRI-responsive and -refractory depressed patients or between SNRI-responsive and -refractory depressed patients. These results suggest that higher plasma IL-6 activity is associated with the refractoriness of depression, and plasma IL-6 levels might be a predictor for response to SSRIs or SNRI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332097     DOI: 10.1016/j.pnpbp.2009.03.020

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  59 in total

Review 1.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

2.  Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.

Authors:  Yoshihiko Matsumoto; Chiara Fabbri; Silvia Pellegrini; Stefano Porcelli; Pierluigi Politi; Silvio Bellino; Caterina Iofrida; Veronica Mariotti; Erika Melissari; Marco Menchetti; Valentina Martinelli; Marco Cappucciati; Paola Bozzatello; Elena Brignolo; Paolo Brambilla; Matteo Balestrieri; Alessandro Serretti
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

3.  Serum BDNF levels before treatment predict SSRI response in depression.

Authors:  Owen M Wolkowitz; Jessica Wolf; Wendy Shelly; Rebecca Rosser; Heather M Burke; George K Lerner; Victor I Reus; J Craig Nelson; Elissa S Epel; Synthia H Mellon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-07-03       Impact factor: 5.067

4.  Inflaming depression.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2011-09       Impact factor: 6.186

5.  Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy Greer; Bruce Grannemann; Abigail Soyombo; Taryn L Mayes; A John Rush; Madhukar H Trivedi
Journal:  Psychoneuroendocrinology       Date:  2017-01-24       Impact factor: 4.905

Review 6.  The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies.

Authors:  Vlad Dionisie; Gabriela Adriana Filip; Mihnea Costin Manea; Mirela Manea; Sorin Riga
Journal:  Inflammopharmacology       Date:  2020-11-08       Impact factor: 4.473

7.  Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine.

Authors:  Mengyang Feng; Nicole A Crowley; Akshilkumar Patel; Yao Guo; Sierra E Bugni; Bernhard Luscher
Journal:  Neuroscience       Date:  2019-03-08       Impact factor: 3.590

8.  Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression.

Authors:  H A Eyre; H Lavretsky; J Kartika; A Qassim; B T Baune
Journal:  Pharmacopsychiatry       Date:  2016-03-07       Impact factor: 5.788

Review 9.  Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process.

Authors:  Helena M Abelaira; Gislaine Z Réus; Fabricia Petronilho; Tatiana Barichello; João Quevedo
Journal:  Neurochem Res       Date:  2014-07-05       Impact factor: 3.996

Review 10.  Toll-Like Receptor Signaling in Depression.

Authors:  Leandra K Figueroa-Hall; Martin P Paulus; Jonathan Savitz
Journal:  Psychoneuroendocrinology       Date:  2020-09-01       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.